Squarepoint’s Gain Therapeutics GANX Stock Holding History

Squarepoint’s Portfolio GANX Stock Details GANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-38,537	Closed	-$68.2K	–	4477
2025 Q3	$68.2K	Buy	+38,537	New	+$65K	﹤0.01%	4179

Other funds holding GANX

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

PCM

Potomac Capital Management New York $115M AUM

Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return

DCM

DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Squarepoint's GANX Position: Q4 2025 in Review

Squarepoint sold out of Gain Therapeutics (GANX) in Q4 2025, closing a stake of 38,537 shares — an estimated $68.2K sold.

Squarepoint first reported a position in GANX in Q3 2025 and held it in 1 quarter. The position peaked at $68.2K in Q3 2025. 48 funds tracked by Wall St. Rank hold GANX as of Q4 2025.

Squarepoint reported no remaining Gain Therapeutics position as of Q4 2025 after selling out during the quarter.
Squarepoint sold 38,537 Gain Therapeutics shares in Q4 2025, an estimated $68.2K.
Squarepoint first reported a position in Gain Therapeutics in Q3 2025 and held it in 1 quarter.
Squarepoint's Gain Therapeutics position peaked at $68.2K in Q3 2025.
48 funds tracked by Wall St. Rank held Gain Therapeutics as of Q4 2025.

Based on Squarepoint's 13F filing for Q4 2025, filed 13 Feb 2026.